O'Neill Institute  |  September 5, 2019

Read the Publication

Hepatitis C (HCV) cases have increased three-and-a- half times from 2010-2016, primarily due to the increase in injection drug use as the United States grapples with the public health crisis of substance use disorder (SUD). Syringe services programs provide a broad range of harm reduction services and can improve the health of persons who inject drugs including reducing HCV transmission.

Read the Big Ideas here.

Related Projects

Hepatitis Policy Project

Latest publications See All

Report

October 14, 2025

Charles Holmes Maggie Little, Ph.D.; Heidi Weimer, J.D., MPH, LL.M; Dylan Green, MPH; Alicia Patterson, Ph.D.; Jonathan Healey; Sydney Luken; Janet Tatenda Bhila; Aleny Couto, MD; Shona Dalal, PhD; Will Fleisher, PhD; Jen Gennai; Rayid Ghani; Peter Godfrey-Faussett; Melissa Goldstein, JD; Kathy Hageman, PhD, MPH; Nina Hasen, PhD; Micheal Ighodaro; Thoko Kalua, MBBS, MSc; Jennifer Miller, PhD; Yogan Pillay, PhD; Anton Pozniak, MD; Miriam Rabkin, MD, MPH; David Ribes, PhD; Lisa Singh, PhD